Qarakal Quantum

Superconducting Qubit Hardware and Full-Stack Quantum Computing Systems

Industrial Technologies
Private
Follow

Company Overview

Snapshot

Founded in September 2024 by Nadav Katz and Alfred Zimmt, Qarakal Quantum operates with 11–50 employees. The company secured a grant from the Israel Innovation Authority in January 2025.

Business overview

Qarakal Quantum is a full-stack quantum computing company specializing in end-to-end systems utilizing superconducting qubit technology. The company develops quantum processing units (QPUs) and a comprehensive software stack to manage novel quantum gates and circuits. By integrating hardware and software, Qarakal designs systems optimized for advanced algorithms, addressing computational tasks beyond classical processors. Its platform aims to improve the speed and efficiency of complex problem-solving in financial services, healthcare, and defense, focusing on applications like risk analysis, fraud detection, and molecular modeling for drug discovery. Qarakal provides scalable B2B quantum solutions, enabling organizations to leverage quantum parallel processing for high-performance optimization and data analysis within the Industrial Technologies sector.

Log in to access full profile

Company Intelligence Q&A

When was Qarakal Quantum founded?
Qarakal Quantum was founded in September 2024.
Who are the founders of Qarakal Quantum?
The company was founded by Nadav Katz and Alfred Zimmt.
What is Qarakal Quantum's primary focus?
Qarakal Quantum focuses on developing end-to-end quantum computing systems using superconducting qubit technology, including both hardware (QPUs) and a comprehensive software stack.
Has Qarakal Quantum received any grants?
In January 2025, Qarakal Quantum secured a grant from the Israel Innovation Authority.
What industries does Qarakal Quantum target with its technology?
Qarakal Quantum targets sectors such as financial services, healthcare, and defense, with applications including risk analysis, fraud detection, and molecular modeling for drug discovery.
Log in to access full profile